| __timestamp | Exelixis, Inc. | Sarepta Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 25111000 | 9757000 |
| Thursday, January 1, 2015 | 37172000 | 1253000 |
| Friday, January 1, 2016 | 191454000 | 5421000 |
| Sunday, January 1, 2017 | 452477000 | 154584000 |
| Monday, January 1, 2018 | 853826000 | 301034000 |
| Tuesday, January 1, 2019 | 967775000 | 380833000 |
| Wednesday, January 1, 2020 | 987538000 | 540099000 |
| Friday, January 1, 2021 | 1434970000 | 701887000 |
| Saturday, January 1, 2022 | 1611062000 | 933013000 |
| Sunday, January 1, 2023 | 1830208000 | 1243336000 |
| Monday, January 1, 2024 | 2168701000 |
Unveiling the hidden dimensions of data
In the competitive landscape of biotechnology, Sarepta Therapeutics, Inc. and Exelixis, Inc. have shown remarkable revenue trajectories over the past decade. Starting in 2014, Exelixis reported a modest revenue of approximately $25 million, while Sarepta began with around $10 million. Fast forward to 2023, Exelixis has surged to nearly $1.83 billion, marking an impressive growth of over 7,200%. Meanwhile, Sarepta has not lagged behind, achieving a revenue of approximately $1.24 billion, reflecting a staggering increase of over 12,600%.
This growth narrative underscores the dynamic nature of the biotech industry, where innovation and strategic advancements drive financial success. As these companies continue to expand their portfolios and market reach, investors and stakeholders keenly watch their next moves. The data highlights the potential for substantial returns in the biotech sector, making it a focal point for future investment opportunities.
Revenue Insights: Johnson & Johnson and Sarepta Therapeutics, Inc. Performance Compared
Takeda Pharmaceutical Company Limited and Exelixis, Inc.: A Comprehensive Revenue Analysis
Alnylam Pharmaceuticals, Inc. vs Exelixis, Inc.: Examining Key Revenue Metrics
Breaking Down Revenue Trends: Teva Pharmaceutical Industries Limited vs Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc. vs Amneal Pharmaceuticals, Inc.: Examining Key Revenue Metrics
Sarepta Therapeutics, Inc. or PTC Therapeutics, Inc.: Who Leads in Yearly Revenue?
Who Generates More Revenue? Sarepta Therapeutics, Inc. or Arrowhead Pharmaceuticals, Inc.
Sarepta Therapeutics, Inc. or Geron Corporation: Who Leads in Yearly Revenue?
Who Generates More Revenue? Sarepta Therapeutics, Inc. or Celldex Therapeutics, Inc.
Exelixis, Inc. and Ionis Pharmaceuticals, Inc.: A Comprehensive Revenue Analysis
Revenue Insights: Exelixis, Inc. and ImmunityBio, Inc. Performance Compared
Exelixis, Inc. vs Amphastar Pharmaceuticals, Inc.: Annual Revenue Growth Compared